Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated April 15, 2025, titled "Dr. Lal PathLabs Becomes South Asia s First Diagnostic Chain to Launch Advanced Test for Amyloidosis".
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Lal PathLabs has announced the launch of an advanced diagnostic test for Amyloidosis, a rare condition involving abnormal protein buildup in organs. The company states it is the first diagnostic chain in South Asia to offer this test. The announcement is based on a press release dated April 15, 2025. This adds a specialised, high-value test to the company's existing diagnostic portfolio, positioning it in the niche area of rare disease diagnostics. No financial details or revenue impact figures were disclosed in the filing.
This launch strengthens Dr. Lal PathLabs' brand as a technology leader in diagnostics and may help attract more referrals and premium patients, though the immediate financial impact is likely small given the rarity of the condition.